Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw unusually-strong trading volume on Thursday . Approximately 1,542,775 shares changed hands during mid-day trading, an increase of 690% from the previous session’s volume of 195,207 shares.The stock last traded at $27.00 and had previously closed at $26.35.

Analyst Ratings Changes

Several equities analysts recently commented on DNTH shares. Raymond James increased their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. Wedbush dropped their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Oppenheimer raised their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Finally, Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Price Performance

The firm has a market cap of $691.46 million, a price-to-earnings ratio of -9.34 and a beta of 1.84. The firm’s 50 day moving average price is $27.58 and its two-hundred day moving average price is $26.64.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the business. Quest Partners LLC boosted its stake in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after buying an additional 1,124 shares during the period. SG Americas Securities LLC acquired a new stake in Dianthus Therapeutics in the second quarter valued at about $112,000. The Manufacturers Life Insurance Company acquired a new stake in Dianthus Therapeutics in the second quarter valued at about $236,000. Fred Alger Management LLC lifted its position in Dianthus Therapeutics by 52.5% in the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after purchasing an additional 3,316 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in Dianthus Therapeutics in the second quarter valued at about $265,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.